UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

March 2029, 2013

Commission File No.: 001-34830

D. MEDICAL INDUSTRIES LTD.

(Translation of registrant’s name into English)

Granot Mobile Post Hefer,

Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Act of 1934.

Yes o No x

~~Attached~~D. ~~hereto~~Medical ~~and~~Industries ~~incorporated~~Ltd. ~~by way of reference herein is a press release issued by~~ (the ~~Registrant, titled:~~ "D.Company") ~~Medical~~hereby ~~Announces~~announces ~~Voluntary SEC Deregistration".~~that:

On March 27, 2013, a lawsuit was filed against the Company, Mr. Yaacov Bar Lev and Mr. Shimon Cohen at the Israeli labor court in Tel Aviv. The lawsuit was filed by Mr. David Schwartz, formerly the chief executive officer and the chairman of the board of directors of the Company. Pursuant to the lawsuit, Mr. Schwartz claims that the Company owes him a total amount of NIS 644,125 due to services granted by Mr. Schwartz to the Company as the chief executive officer and chairman of the board of directors of the Company. The Company has thirty days to respond to the lawsuit. As of the date of this report, the Company reviews the lawsuit to evaluate the claims included therein.

The Special General Meeting of Shareholders (the "Meeting"), originally scheduled to take place on March 27, 2013 (see the Company's report on Form 6-K furnished to the Securities and Exchanges Commission on February 21, 2013), is postponed to April 3, 2013 at 11:00 a.m. (Israel time). The postponement is due to the lack of legal quorum available at the original date of the Meeting.

·	The previously reported negotiations for the sale of the Company's subsidiaries' intellectual property rights (see the Company's report on Form 6-K furnished to the Securities and Exchanges Commission on November 8, 2012), were terminated as of March 21, 2013.

On March 12, 2013, Mr. Youval Mor-Mously was appointed as member of the Company's board of directors, effective immediately. Mr. Mor-Mously was also appointed as a member of the board of directors' compensation and the board directors' committee for the examination of financial statements. The Company's board of directors has determined that Mr. Mor-Mously is independent under the requirements of the Israeli Companies Law, 1999. Mr. Mor-Mously is an attorney-at-law admitted for the practice of law in the State of Israel. He has an LL.B. from Tel Aviv University, Israel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 2029, 2013 D. MEDICAL INDUSTRIES LTD. (Registrant) By: /s/ Yaacov Bar Lev —————————————— Yaacov Bar Lev Chairman

News Release

For Immediate Release

D. Medical Announces Voluntary SEC Deregistration

Granot, Israel – March 20, 2013 – D. Medical Industries Ltd. (TASE:DMED) ("D. Medical" or the "Company"), announced today that its Board of Directors approved the filing of a Form 15F with the Securities and Exchange Commission ("SEC") to voluntarily deregister its ordinary shares under the Securities Exchange Act of 1934 (the "Exchange Act"). The Company intends to file the Form 15F on or about March 29, 2013. The Company's reporting obligations under the Exchange Act will be suspended immediately upon the filing of Form 15F and will terminate 90 days thereafter if there are no objections from the SEC. The Company reserves the right to delay or withdraw the filing for any reason prior to their effectiveness.

Following the deregistration, the Company’s ordinary shares may continue to be quoted on the OTC Markets Group Inc. electronic quotation service (the "Pink Sheets") if market makers commit to make a market in the Company’s shares. However, the Company has not arranged for quotation on the Pink Sheets or listing or quotation on any other exchange or quotation medium within the U.S. Thus, the Company can provide no assurance that trading in its ordinary shares will be quoted on the Pink Sheets or otherwise. The Company's ordinary shares will continue to trade on the Tel Aviv Stock Exchange Ltd. (TASE: DMED)

In deciding to voluntarily deregister its ordinary shares, the Company's Board of Directors considered several factors, including the following:

● low U.S. trading volume; ● high public company costs in the U.S., including those associated with preparation and filing of the Company's periodic reports with the SEC; ● significant management time spent on U.S. regulatory compliance; and ● the potential impact of deregistration on Company shareholders resident in the U.S.

Company Contact:

Orly Benizri Solomon

Chief Executive Officer

D. Medical Industries Ltd.

T: +972-70-2508715

orly@dmedicalindustries.com

Filing Compare · D. MEDICAL INDUSTRIES LTD.